Recent Advances and the Future of Antibody Engineering

As single-use technologies have been widely adopted by the pharmaceutical industry, there has been a corresponding shift in responsibility from end-users to suppliers.

DNA defines who we are. And like anything else, sometimes there are mistakes – mutations in genes that can cause life-lasting conditions. But what if broken genes could be repaired? How many patients could we help in the years ahead? This is the promise and possibility of genome editing.

The webinar will focus on the relationship between analytics of biotherapeutic products and the interpretation of data to build and support a solid regulatory Chemistry, Manufacturing and Control (CMC) strategy. The importance of data interpretation is illustrated in the development of biosimilars and new biological entities, as well as in regulatory specifications regarding biotherapeutic products.

T cells play a critical role in the adaptive immune response. In naive T cells, binding of the T-cell receptor (TCR) to peptides complexed with major histocompatibility complex triggers an intricate signaling mechanism leading to T-cell activation, proliferation, and production of cytokines. Modulating the TCR signaling pathway using biologics, small molecules, or genetic engineering is highly relevant to many therapeutic areas, including cancer immunotherapy, adoptive cell therapy, vaccine development, and autoimmune disease.